Kymera IPO Presentation Deck

VERTEX Vertex collaboration signed May 2019 - $70 million total, including $50 million upfront cash and $20 million equity investment Collaboration covers up to 6 targets in disease areas outside of Kymera's core areas of focus in oncology and inflammation. Financial terms: Strategic Collaborations Eligible for >$1 billion in payments Development, regulatory, and commercial milestones; option exercise payments Tiered royalties on future net sales on any products from collaboration Vertex option at DC and bears all clinical, regulatory and other . KYMERA H i SANOFI Sanofi collaboration signed July 2020 $150 million upfront payment + potential milestones of over $2 billion and tiered royalties Collaboration covers two programs: IRAK4 program in immune-inflammatory disease Second earlier-stage program Financial terms: Upfront payment + development, regulatory, and commercial milestones Tiered royalties on future net sales on any products from collaboration Kymera advances IRAK4 through Phase 1; Sanofi performs/funds all other clinical work Kymera retains U.S. opt-in rights for both programs: - Kymera decision before phase 3 to co-develop and co-promote Under opt-in, companies equally share development costs and profits/losses in the US Kymera retains all rights to IRAK4 in oncology

View entire presentation